S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Price, News & Analysis

$7.34
+0.48 (+7.00%)
(As of 03/27/2024 ET)
Today's Range
$6.77
$7.37
50-Day Range
$4.33
$8.35
52-Week Range
$1.63
$8.83
Volume
2.11 million shs
Average Volume
2.95 million shs
Market Capitalization
$728.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Fate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
7.4% Downside
$6.80 Price Target
Short Interest
Bearish
15.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.78mentions of Fate Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$199,732 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

310th out of 939 stocks

Biological Products, Except Diagnostic Industry

44th out of 154 stocks

FATE stock logo

About Fate Therapeutics Stock (NASDAQ:FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Stock Price History

FATE Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Fate Therapeutics (NASDAQ:FATE) Trading Down 7%
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
FATE Apr 2024 5.000 put
FATE Aug 2024 5.000 put
FATE Apr 2024 7.500 put
FATE Mar 2024 10.000 put
TD Cowen Keeps Their Buy Rating on Merus (MRUS)
Q4 2023 Fate Therapeutics Inc Earnings Call
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
181
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.80
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-7.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$-160,930,000.00
Net Margins
-253.30%
Pretax Margin
-253.30%

Debt

Sales & Book Value

Annual Sales
$63.53 million
Book Value
$3.74 per share

Miscellaneous

Free Float
94,236,000
Market Cap
$728.42 million
Optionable
Optionable
Beta
1.67
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

FATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price target for 2024?

10 brokers have issued 12-month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $6.80 in the next year. This suggests that the stock has a possible downside of 7.4%.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2024?

Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE shares have increased by 96.3% and is now trading at $7.34.
View the best growth stocks for 2024 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.85 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 38.17% and a negative net margin of 253.30%. During the same quarter in the previous year, the firm earned ($0.58) EPS.

What ETF holds Fate Therapeutics' stock?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Vanguard Group Inc. (9.36%), Point72 Asset Management L.P. (3.54%), Monaco Asset Management SAM (2.21%), Federated Hermes Inc. (1.88%) and Vestal Point Capital LP (1.31%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FATE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners